Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,274.05 -131.61 (-0.34%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,150.85 +6.72 (+0.08%) Bitcoin USD
57,427.66 -4,213.85 (-6.84%) CMC Crypto 200
1,236.01 -103.05 (-7.69%)
JNJ Sep 2024 165.000 call
| Previous close | 0.6400 |
| Open | 0.6600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 165.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.6400 - 0.7100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ReutersJ&J advances $6.475 billion settlement of talc cancer lawsuits
Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer, the company said Wednesday in a statement. The deal would allow it to resolve the lawsuits through a third bankruptcy filing of a subsidiary company. It will begin a three month voting period in hopes of reaching consensus on a settlement of all current and future ovarian cancer claims.
Business WireJohnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual "Prepackaged" Reorganization
NEW BRUNSWICK, N.J., May 01, 2024--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced a proposed Plan of Reorganization (the "Plan") by its subsidiary, LLT Management LLC ("LLT"), for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States.
- Reuters
J&J, Bristol Myers lose challenges to US drug price negotiation program
A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties. U.S. District Judge Zahid Quraishi in Trenton, New Jersey, became the fourth federal judge to uphold the program, one of Democratic President Joe Biden's signature initiatives, against drug industry challenges, rejecting their argument that it was an illegal taking of their property. "In short, defendants are not taking drugs from plaintiffs," Quraishi wrote, adding that they were free to stop participating in Medicare if they did not want to negotiate.
